Filing Flows › Pacira BioSciences (PCRX) › Q3 2025
Pacira BioSciences (PCRX) Q3 2025 earnings results (third quarter 2025)
10-Q filed Nov 6, 2025
Pacira BioSciences (PCRX) reported revenue of $180M for the third quarter 2025 (Q3 2025), +6% from a year earlier and -0.9% from the quarter before. Operating margin was 3.5%, net earnings $5.4M (3.0% of revenue).
Pacira BioSciences, Q3 2025: revenue $180M (+6% year over year), operating margin 3.5%, net earnings $5.4M, operating cash flow $60.8M. The chart follows the revenue to costs, profit and cash.
| Q3 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $180M | -0.9% | +6% |
| Operating profit | $6.4M | -25% | — |
| Net earnings | $5.4M | — | — |
| Operating cash flow | $60.8M | +406% | +13% |
| Free cash flow | $57.0M | +512% | +14% |
What changed
Revenue was $179.5M in Q3 2025, up 6% year over year and down 1% from the previous quarter. EXPAREL was the largest line at 78% of revenue. EXPAREL added $7.9M year over year (up 6%), 72% of the total change.
Operating profit was $6.4M, a 3.5% margin (up 86.3 points year over year). Total costs fell 44% while revenue rose 6%. The fastest-growing cost line was Research & development (+36%). Net earnings were $5.4M. The effective tax rate was 43.0%. Non-operating items added $3.2M, 33% of pre-tax earnings, so the bottom line overstates operating performance.
Operating cash flow was $60.8M (up 13% year over year), 1120% of net earnings. Non-cash charges added back $21.2M of depreciation and amortization and $14.0M of share-based compensation. Working capital and other items added $20.2M. Capital expenditures of $3.9M left free cash flow of $57.0M.
Questions
What was Pacira BioSciences' revenue in the third quarter 2025?
Pacira BioSciences (PCRX) reported revenue of $180M for the third quarter 2025 (Q3 2025), +6% from a year earlier and -0.9% from the quarter before.
Was Pacira BioSciences profitable in the third quarter 2025?
Operating profit was $6.4M (3.5% of revenue) and net earnings $5.4M.
Source: Pacira BioSciences 10-Q on SEC EDGAR.